Abstract:Background: Although oxidative phosphorylation (OXPHOS) is the main ATP source in primary prostate cancer, as the tumor progresses to castration resistance and/or metastatic disease, glycolysis becomes increasingly prevalent. Dependence on glycolysis can further increase under hypoxic conditions found in advanced cancers. We previously demonstrated that a novel small molecule, BKIDC-1553, inhibits proliferation and tumor growth of prostate cancer cell lines and xenografts through a hexokinase-2 (HK2) dependent inhibition of glycolysis. HK2 is a glucose 6-phosphorylating enzyme that works in conjunction with glucose transporter-1 (GLUT1) to drive glycolysis in cells. While our previous work suggests that BKIDC-1553 works primarily through a HK2 dependent mechanism, the objective of this current project is to further examine how expression and function of HK2 and GLUT1 are altered in response to BKIDC-1553 treatment. Methods: Hypoxic conditions are common in late-stage prostate cancer. Effects of hypoxia on cell proliferation and expression levels of HK1, HK2, and GLUT1 were examined with and without BKIDC-1553 treatment. To examine role of HK1, HK2, and GLUT1 in response to BKIDC-1553 treatment, we created CRISPR knockouts and shRNA knockdowns of HK1 and HK2 in the LNCaP prostate cancer cell line. GLUT1 was inhibited using a commercially available inhibitor, BAY-876. PCR and Western blots were used to confirm expression levels of HK1, HK2, and GLUT1. MTS proliferation assays were used to examine effect of KO and KD on response to BKIDC-1553 and BAY-876. Results: GLUT1 levels, but not HK1 or 2, increased at 72 hrs under hypoxic conditions. HK1, HK2, and GLUT1 levels all increased in cells in response to 144 hrs of BKIDC-1553 compared with 72 hrs treatment in both normoxic and hypoxic conditions. The KO and KD studies were all conducted in normoxic conditions. Westerns blots demonstrated that HK2 KO, but not HK1 KO, results in increased levels of GLUT1. HK1 or HK2 KD, however, did not alter GLUT1 levels. HK2 KD cells, with GLUT1 levels remaining the same, displayed less growth inhibition than control cells in response to BKIDC-1553 treatment, while HK2 KO cells, with increased levels of GLUT1, remained sensitive to BKIDC-1553. Because GLUT1 levels increase in response to HK2 KO, we wanted to see if inhibiting GLUT1 in these cells could decrease their proliferation. We found that KO cells were indeed more sensitive to growth inhibition of BAY-876. Conclusion/Summary: These studies indicate that KO of HK2 increases levels of GLUT1. These cells remain sensitive to BKIDC-1553 treatment, which could in part be due to the cells' continued reliance on glycolysis through increased GLUT1. A continued reliance on glycolysis allows BKIDC-1553 to continue to inhibit cell growth. Future studies examining how combination treatment with BKIDC-1553 and BAY-876 affects growth of advanced prostate cancer cells is underway. Citation Format: Cynthia Sprenger, Mika Munari, Shihua Sun, Kathryn Soriano Epilepsia, Stephen Plymate. Alterations in glycolytic pathway enzymes and metabolic plasticity in prostate cancer progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 448.

Alternol Eliminates Excessive ATP Production by Disturbing Krebs Cycle in Prostate Cancer.

Alternol Exerts Prostate‐selective Antitumor Effects Through Modulations of the AMPK Signaling Pathway

Natural compound Alternol exerts a broad anti-cancer spectrum and a superior therapeutic safety index in vivo

Alternol Triggers Immunogenic Cell Death Via Reactive Oxygen Species Generation

Abstract A06: Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness

Alternol Sensitizes Renal Carcinoma Cells to TRAIL-Induced Apoptosis

Alternol, a Natural Compound, Exerts an Anti‐tumour Effect on Osteosarcoma by Modulating of STAT3 and ROS/MAPK Signalling Pathways

Cell Growth Inhibition, G2M Cell Cycle Arrest, and Apoptosis Induced by the Novel Compound Alternol in Human Gastric Carcinoma Cell Line MGC803.

Growth Inhibition and Apoptosis Induction by Alternol in Pancreatic Carcinoma Cells.

Natural compound Alternol actives multiple endoplasmic reticulum stress-responding pathways contributing to cell death

Retraction Note To: Alternol Inhibits Proliferation and Induces Apoptosis in Mouse Lymphocyte Leukemia (L1210) Cells.

Alternol inhibits the proliferation and induces the differentiation of the mouse melanoma B16F0 cell line

Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelial-to-mesenchymal transition

PDHA1 gene knockout in prostate cancer cells results in metabolic reprogramming towards greater glutamine dependence.

Abstract 448: Alterations in glycolytic pathway enzymes and metabolic plasticity in prostate cancer progression

Dankasterone a induces prostate cancer cell death by inducing oxidative stress

Aloperine Executes Antitumor Effects Through the Induction of Apoptosis and Cell Cycle Arrest in Prostate Cancer in Vitro and in Vivo

Alteronol Enhances the Anti-tumor Activity and Reduces the Toxicity of High-Dose Adriamycin in Breast Cancer

Oleanolic acid induces metabolic adaptation in cancer cells by activating the AMP-activated protein kinase pathway.

Alterperylenol As a Novel Thioredoxin Reductase Inhibitor Induces Liver Cancer Cell Apoptosis and Ferroptosis

Anti-prostate cancer metabolites from the soil-derived Aspergillus neoniveus